Evidence map›Paper›PMID 39202998›Full record

ArticleMolecules (Basel, Switzerland)2024

β,β-Dimethylacrylalkannin, a Natural Naphthoquinone, Inhibits the Growth of Hepatocellular Carcinoma Cells by Modulating Tumor-Associated Macrophages.

Li-Sha Shen, Zesi Lin, Rui-Hong Gong, Yu-Shan Lin, Xing-Fang Qiao, Qian-Mei Hu, Wei-Han Qin, Sibao Chen, Yong Yang, Guo-Qing Chen

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Li-Sha ShenChongqing Academy of Chinese Materia Medica, Chongqing 400065, China.
Zesi LinSouthern Medical University of Hospital of Integrated Traditional Chinese Medicine and Western Medicine, Southern Medical University, Guangzhou 510515, China.
Rui-Hong GongDepartment of Food Science and Nutrition, The Hong Kong Polytechnic University, Hung Hom, Hong Kong 999077, China.
Yu-Shan LinState Key Laboratory of Chinese Medicine and Molecular Pharmacology (Incubation), The Hong Kong Polytechnic University Shenzhen Research Institute, Shenzhen 518057, China.
Xing-Fang QiaoChongqing Academy of Chinese Materia Medica, Chongqing 400065, China.
Qian-Mei HuChongqing Academy of Chinese Materia Medica, Chongqing 400065, China.
Wei-Han QinChongqing Academy of Chinese Materia Medica, Chongqing 400065, China.ORCID 0000-0002-5252-651X
Sibao ChenDepartment of Food Science and Nutrition, The Hong Kong Polytechnic University, Hung Hom, Hong Kong 999077, China.ORCID 0000-0003-1539-9192
Yong YangChongqing Academy of Chinese Materia Medica, Chongqing 400065, China.
Guo-Qing ChenDepartment of Food Science and Nutrition, The Hong Kong Polytechnic University, Hung Hom, Hong Kong 999077, China.ORCID 0000-0002-3671-5257

Funding

Chongqing Science and Technology Commission CSTB2023NSCQ-MSX0155Innovation and Technology Fund-Mainland-Hong Kong Joint Funding Scheme MHP/010/20Shenzhen Science and Technology Innovation Commission JCYJ20220531090802006The Hong Kong Polytechnic University Shenzhen Research Institute Life Science Research Start-up Fund I2023A008Traditional Chinese Medicine Bureau of Guangdong Province 202404101916049020
6 · The paper itself

Abstract

Tumor-associated macrophages (TAMs) are pivotal in the tumor microenvironment (TME) of hepatocellular carcinoma (HCC), influencing various stages from initiation to metastasis. Understanding the role of TAMs in HCC is crucial for developing novel therapeutic strategies. Macrophages exhibit plasticity, resulting in M1 and M2 phenotypes, with M1 macrophages displaying antitumor properties and M2 macrophages promoting tumor progression. Targeting TAMs to alter their polarization could offer new avenues for HCC treatment. β,β-dimethylacrylalkannin (DMAKN), a natural naphthoquinone, has gained attention for its antitumor properties. However, its impact on TAMs modulation remains unclear. This study investigates DMAKN's modulation of TAMs and its anti-HCC activity. Using an in vitro model with THP-1 cells, we induced M1 macrophages with LPS/IFN-γ and M2 macrophages with IL-4/IL-13, confirming polarization with specific markers. Co-culturing these macrophages with HCC cells showed that M1 cells inhibited HCC growth, while M2 cells promoted it. Screening for non-toxic DMAKN concentrations revealed its ability to induce M1 polarization and enhance LPS/IFN-γ-induced M1 macrophages, both showing anti-HCC effects. Conversely, DMAKN suppressed IL-4/IL-13-induced M2 polarization, inhibiting M2 macrophages' promotion of HCC cell viability. In summary, DMAKN induces and enhances M1 polarization while inhibiting M2 polarization of macrophages, thereby inhibiting HCC cell growth. These findings suggest that DMAKN has the potential to regulate TAMs in HCC, offering promise for future therapeutic development.

Indexed as

Carcinoma, HepatocellularCell ProliferationLiver NeoplasmsNaphthoquinonesTumor-Associated MacrophagesAntineoplastic AgentsCell Line, TumorHumansTHP-1 CellsTumor MicroenvironmentalkanninAntineoplastic AgentsNaphthoquinonesco-culturehepatocellular carcinomamacrophage polarizationTHP-1β,β-dimethylacrylalkannin

Identifiers

PMID39202998
PMCPMC11357245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.